InsiderTrades.com logo
Christopher Yea net worth and biography
  • Phone
  • Email
  • Website

Christopher Yea Biography and Net Worth

Insider of KalVista Pharmaceuticals
Chris holds a BSc and PhD in Biochemistry from the University of Bristol, UK. Following post-doctoral work, he spent several years at Roussel-UCLAF and Hoechst Marion Roussel before joining Ferring Pharmaceuticals. Chris led the Biology group and was responsible for transition of candidates into development. In 2008, Chris co-led the spin-out of Vantia Ltd and most recently was Chief Operating Officer where he was responsible for development activities through Phase 3 trials.

In his position as Chief Development Officer, Chris is responsible for all development-related activities within KalVista Pharmaceuticals.

What is Christopher Yea's net worth?

The estimated net worth of Christopher Yea is at least $1.61 million as of August 19th, 2024. Dr. Yea owns 84,467 shares of KalVista Pharmaceuticals stock worth more than $1,607,829 as of March 27th. This net worth estimate does not reflect any other investments that Dr. Yea may own. Learn More about Christopher Yea's net worth.

How do I contact Christopher Yea?

The corporate mailing address for Dr. Yea and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at [email protected]. Learn More on Christopher Yea's contact information.

Has Christopher Yea been buying or selling shares of KalVista Pharmaceuticals?

Christopher Yea has not been actively trading shares of KalVista Pharmaceuticals in the last ninety days. Most recently, Christopher Yea sold 7,102 shares of the business's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $12.01, for a transaction totalling $85,295.02. Following the completion of the sale, the insider now directly owns 84,467 shares of the company's stock, valued at $1,014,448.67. Learn More on Christopher Yea's trading history.

Who are KalVista Pharmaceuticals' active insiders?

KalVista Pharmaceuticals' insider roster includes Paul Audhya (Insider), Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Benjamin Palleiko (Chief Executive Officer and Director), Brian Piekos (CFO), Michael Smith (VP), Nicole Sweeny (Insider), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.

Are insiders buying or selling shares of KalVista Pharmaceuticals?

During the last year, KalVista Pharmaceuticals insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $235,500.00. During the last year, insiders at the specialty pharmaceutical company sold shares 24 times. They sold a total of 140,441 shares worth more than $2,058,188.46. The most recent insider tranaction occured on March, 9th when CEO Benjamin L Palleiko sold 6,693 shares worth more than $107,623.44. Insiders at KalVista Pharmaceuticals own 4.3% of the company. Learn More about insider trades at KalVista Pharmaceuticals.

Information on this page was last updated on 3/9/2026.

Christopher Yea Insider Trading History at KalVista Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/19/2024Sell7,102$12.01$85,295.0284,467View SEC Filing Icon  
5/18/2023Sell2,604$10.14$26,404.5637,310View SEC Filing Icon  
11/18/2022Sell1,139$5.44$6,196.1634,232View SEC Filing Icon  
8/2/2021Sell5,000$20.52$102,600.008,234View SEC Filing Icon  
5/3/2021Sell5,000$24.84$124,200.0042,969View SEC Filing Icon  
2/23/2021Sell15,000$33.59$503,850.0062,169View SEC Filing Icon  
10/29/2020Sell5,000$17.48$87,400.0062,969View SEC Filing Icon  
10/20/2020Sell7,942$17.49$138,905.5876,315View SEC Filing Icon  
10/16/2020Sell914$17.00$15,538.0081,955View SEC Filing Icon  
12/16/2019Sell3,010$17.05$51,320.5083,168View SEC Filing Icon  
12/13/2019Sell1,500$17.05$25,575.0083,168View SEC Filing Icon  
4/22/2019Sell7,355$26.04$191,524.2090,324View SEC Filing Icon  
1/25/2019Sell5,453$17.06$93,028.1888,422View SEC Filing Icon  
1/23/2019Sell1,902$17.01$32,353.0284,271View SEC Filing Icon  
See Full Table

Christopher Yea Buying and Selling Activity at KalVista Pharmaceuticals

This chart shows Christopher Yea's buying and selling at KalVista Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals logo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $19.04
Low: $18.91
High: $19.95

50 Day Range

MA: $15.95
Low: $14.40
High: $18.95

2 Week Range

Now: $19.04
Low: $9.23
High: $19.95

Volume

1,014,265 shs

Average Volume

1,028,742 shs

Market Capitalization

$962.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A